Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1983 1
1985 1
1987 3
1988 2
1989 4
1992 1
1996 4
1997 2
1998 2
1999 1
2000 1
2001 1
2002 1
2005 2
2006 2
2007 2
2008 2
2009 1
2010 2
2011 1
2012 2
2013 4
2014 6
2015 3
2016 4
2017 2
2018 2
2019 2
2021 1
2023 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
Geyer CE Jr, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, D'Hondt V, Conlin AK, Guarneri V, Wapnir IL, Jackisch C, Arce-Salinas C, Fasching PA, DiGiovanna MP, Crown JP, Wuelfing P, Shao Z, Rota Caremoli E, Bonnefoi HR, Hennessy BT, Stamatovic L, Castro-Salguero H, Brufsky AM, Knott A, Siddiqui A, Lambertini C, Boulet T, Nyawira B, Restuccia E, Loibl S; KATHERINE Study Group. Geyer CE Jr, et al. N Engl J Med. 2025 Jan 16;392(3):249-257. doi: 10.1056/NEJMoa2406070. N Engl J Med. 2025. PMID: 39813643 Clinical Trial.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Romond EH, et al. N Engl J Med. 2005 Oct 20;353(16):1673-84. doi: 10.1056/NEJMoa052122. N Engl J Med. 2005. PMID: 16236738 Free article. Clinical Trial.
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Perez EA, et al. Among authors: romond eh. J Clin Oncol. 2014 Nov 20;32(33):3744-52. doi: 10.1200/JCO.2014.55.5730. Epub 2014 Oct 20. J Clin Oncol. 2014. PMID: 25332249 Free PMC article. Clinical Trial.
Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Electronic address: bc.overview@ndph.ox.ac.uk; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Electronic address: bc.overview@ndph.ox.ac.uk, et al. Lancet. 2025 Aug 9;406(10503):603-614. doi: 10.1016/S0140-6736(25)01013-X. Lancet. 2025. PMID: 40783288 Free article.
Systemic therapy for HER2-positive early-stage breast cancer.
Mathew A, Romond EH. Mathew A, et al. Among authors: romond eh. Curr Probl Cancer. 2016 Mar-Aug;40(2-4):106-116. doi: 10.1016/j.currproblcancer.2016.09.002. Epub 2016 Sep 17. Curr Probl Cancer. 2016. PMID: 27816189 Review.
Metastatic angiosarcoma and kasabach-merritt syndrome.
Massarweh S, Munis A, Karabakhtsian R, Romond E, Moss J. Massarweh S, et al. Among authors: romond e. Rare Tumors. 2014 Jun 13;6(2):5366. doi: 10.4081/rt.2014.5366. eCollection 2014 May 13. Rare Tumors. 2014. PMID: 25002952 Free PMC article.
Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy.
Jatoi I, Bandos H, Jeong JH, Anderson WF, Romond EH, Mamounas EP, Wolmark N. Jatoi I, et al. Among authors: romond eh. J Natl Cancer Inst. 2015 Oct 30;108(1):djv304. doi: 10.1093/jnci/djv304. Print 2016 Jan. J Natl Cancer Inst. 2015. PMID: 26518884 Free PMC article.
60 results